Roche Sees Minimal Elecsys Financial Impact In Wake Of IGEN Court Order
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics expects only a "small percentage" of its Elecsys line of immunoassay analyzers incorporating IGEN's Origen technology will be affected by an upcoming court-ordered transfer of Elecsys physician office laboratory accounts to IGEN.